

R^1 is selected from



y is 1-16, and

R^2 is selected from



in the manufacture of a medicament for the treatment of human solid tumours expressing HER2, wherein the human solid tumour expressing HER2 is endometrial cancer.

In another aspect, there is provided the use of a combination of a compound as disclosed herein with a therapeutic antibody and/or a chemotherapeutic agent, in the manufacture of a medicament for the treatment of endometrial cancer.

In one example, there is disclosed a pharmaceutical composition comprising a compound as disclosed herein or a combination as disclosed herein, and one or more pharmaceutically acceptable excipients.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. In vitro USC cell line cytotoxicity: SYD985 versus T-DM1.

Figure 2. In vivo USC cell line xenograft efficacy in mice: SYD985 versus T-DM1 after multiple injections.

6. The use according to any one of claims 1 to 5, wherein the endometrial cancer is HER2 IHC 2+ or 1+.
7. The use according to any one of claims 1 to 6, wherein the endometrial cancer is HER2 FISH negative.
8. Use of a combination of a compound according to any one of claims 1 to 7 with a therapeutic antibody and/or a chemotherapeutic agent, in the manufacture of a medicament for the treatment of endometrial cancer.
9. The use according to claim 8, wherein the endometrial cancer is uterine serous carcinoma.
10. The use according to claim 8 or 9, wherein the therapeutic antibody is pertuzumab and the chemotherapeutic agent is a taxane, an anthracycline or a tyrosine kinase inhibitor.